Skip to content

Promising preliminary outcomes from stereotactic radiotherapy for kidney cancer

8.5.2024 Categories: Press releases
Research Treatments
In Finland, about 1,000 people are diagnosed with kidney cancer each year. Up to half of these are found by chance during abdominal scans that are carried out for unrelated reasons. Localised kidney cancer is always primarily treated with surgery, which involves total or partial removal of the kidney. In light of the latest preliminary research findings, promising treatment results can also be achieved with stereotactic radiotherapy. In early 2024, Docrates became one of the first service providers in Finland to perform stereotactic radiotherapy on a patient with localised kidney cancer.

At the American Society for Radiation Oncology (ASTRO) meeting at the end of 2023, promising results were presented from a phase 2 FASTRACK II trial of stereotactic radiotherapy (SABR) in the treatment of localised kidney cancer.

– When I heard about the research results at the meeting, I immediately thought that this would offer a possible new form of treatment for patients with localised kidney cancer for whom surgery is not possible for one reason or another, says Associate Professor Leila Vaalavirta from Docrates Cancer Center.

The objective of the study was to investigate the efficacy of stereotactic radiotherapy (SABR) in patients with localised kidney cancer for whom surgery was not possible for medical or other reasons. The aim was to evaluate both the efficacy and safety of the treatment. The study was comprised of 70 patients for whom surgery was not a viable treatment option. The average age of the patients was 77 years. Depending on the size of the tumor, the patients underwent either one or three sessions of stereotactic radiotherapy. According to the study, localised cancer progression was not found in any of the SABR research patients after one year of radiotherapy, and any adverse reactions were minor and generally mild. Based on the study, stereotactic radiotherapy (SABR) appears to be a promising treatment option for localised kidney cancer.

The study was published in The Lancet Oncology, a prestigious journal covering cancer research, in March 2024. Immediately after the publication of the study, Docrates became one of the first service providers in Finland to perform stereotactic radiotherapy on a patient with localised kidney cancer. The patient’s health status and other underlying diseases prevented cancer surgery. The patient contacted Docrates which had been their previous service provider in the treatment of prostate cancer.

– We were able to immediately make use of the latest research results as the patient’s clinical picture and situation enabled them to be treated with the radiotherapy methods implemented in the study. The patient has now received a full course of radiotherapy without experiencing any immediate side effects, and the current plan is to have a follow-up appointment once every three months. We at Docrates are pleased to be able to immediately use the latest research results and, therefore, offer more and more patients individualised and effective treatment without delay, says Vaalavirta.

Docrates Cancer Center uses the latest international research data in the individual treatment of patients with cancer. Docrates has the opportunity to introduce new diagnostic methods and treatments without delay that are not yet routinely used or in use elsewhere. The Cancer Center employs a number of specialists in cancer treatment and diagnostics with extensive experience and knowledge of cancer.

Learn more about the study


About 1,000 new kidney cancers are diagnosed annually in Finland

The most common type of kidney cancer is clear cell renal cancer (70%). Other types of kidney cancer include papillary (10%) and chromophobe (5%). The most well-known hereditary cause of kidney cancer is Von Hippel-Lindau Syndrome.

Localised kidney cancer is always primarily treated with surgery, which involves total or partial removal of the kidney. Surgical treatment of individual metastases is possible on a case-by-case basis. In recent years, a number of new medicines have been introduced for the treatment of metastatic kidney cancer. The latest medicines boost the body’s defence system against cancer cells.

Follow-up of the treatment of a kidney cancer patient is important. The basic blood count, renal function and bone health are monitored every six months. The condition of the lungs and abdomen is assessed by X-rays.

For more information contact our booking service

Read the stories of our cancer patients

The story of a breast cancer patient: You have to focus on the good things, even if the world keeps spinning

It is December, and the first long year of the pandemic is nearing its end. A couple is sitting in...

Read more

Cancer diagnosis did not stop Mika Piltz: “I’m grateful that quality of life can be improved with the right treatment methods”

Getting diagnosed with prostate cancer turned the world of Mika Piltz, 54, upside down in 2021. His calendar was filled...

Janos Uotila’s prostate cancer was treated in a private cancer hospital

There's a man in the hospital lobby with a smile on his face. Janos Uotila, 45, has become familiar with...

Malcolm: Today, I appreciate more time spent with my family

Malcolm Clark, 65, was diagnosed with prostate cancer in late 2017. He didn’t feel sick, so the information about having...

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00